Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 4/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | RARG | P13631 | 3/20 | 0.32 |
| ▸ | RARA | P10276 | 2/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9004834 | 0.87 | CYP1A2 (0.40) | FFAR3RARBRXRARARGRARA | |
| SCHEMBL22077241 | 0.82 | SLC6A3 (0.34) | FFAR3CYP3A4 | |
| SCHEMBL11394565 | 0.77 | MAPT (0.40) | FFAR3RXRACYP3A4CYP1A2 | |
| SCHEMBL3783619 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL8987261 | 0.73 | — | — | |
| SCHEMBL29216142 | 0.72 | FFAR3 (0.31) | FFAR3 | |
| SCHEMBL673146 | 0.72 | KRAS (0.38) | FFAR3CYP1A2 | |
| SCHEMBL22108771 | 0.72 | RXRA (0.31) | FFAR3RXRA | |
| SCHEMBL9342959 | 0.70 | CYP1A2 (0.51) | RARBRXRARARGRARACYP3A4 | |
| SCHEMBL2874656 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4574821-B1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-3893889-B1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260001867-A1 | THR BETA RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2026-01-01 | — | — | US | disclosed |
| US-12459926-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12365669-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4574821-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | Terns, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12338232-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250179054-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250179053-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4529954-A2 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | Terns, Inc. (US) | 2025-04-02 | — | — | EP | disclosed |
| US-11084802-B2 | THRβ receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-113194958-A | THR beta receptor agonist compound and preparation method and application thereof | 拓臻股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-11034676-B2 | THRB receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034676-B2 | THRB receptor agonist compound and preparation method and use thereof | Terns, Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200399249-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200399249-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| CN-111320609-A | THR β receptor agonist compound and preparation method and application thereof | 拓臻股份有限公司 | 2020-06-23 | — | — | CN | disclosed |
| WO-2020123827-A1 | THRΒ RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | Terns, Inc. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200190064-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200190064-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | TERNS PHARMACEUTICALS, INC. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179054-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, TRHR | FFAR3 97/4885RARB 818/4885RXRA 1327/4885 |
| US-20260001867-A1 | THR BETA RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, ADRB1 | FFAR3 68/4885RARB 1726/4885RXRA 1644/4885 |
| US-20250179053-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, TRHR | FFAR3 97/4885RARB 818/4885RXRA 1327/4885 |
| US-20200190064-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, TRHR | FFAR3 97/4885RARB 818/4885RXRA 1327/4885 |
| US-12459926-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | FFAR3 92/4885RARB 1123/4885RXRA 1250/4885 |
| US-12365669-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | FFAR3 92/4885RARB 1123/4885RXRA 1250/4885 |
| US-11034676-B2 | THRB receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | FFAR3 97/4885RARB 818/4885RXRA 1327/4885 |
| US-11084802-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | FFAR3 92/4885RARB 1123/4885RXRA 1250/4885 |
| US-12338232-B2 | THRβ receptor agonist compound and preparation method and use thereof | THRB, THRA, TRHR | FFAR3 92/4885RARB 1123/4885RXRA 1250/4885 |
| US-20200399249-A1 | THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | THRB, THRA, TRHR | FFAR3 97/4885RARB 818/4885RXRA 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.